SCL Science secures European patent registration for ‘Innosil Plus DL’
SCL Science’s surgical hemostatic agent “InnoSeal Plus DL” has received a decision for patent registration in Europe.
The domestically developed surgical hemostatic agent “InnoSeal Plus DL” has received a decision for patent registration in Europe, paving the way for accelerated entry into the European market. The company stated that it plans to pursue local certification and distribution network establishment with a focus on Germany.
SCL Science announced on the 21st that the patent related to its surgical hemostatic patch “InnoSeal Plus DL” has received a decision for registration from the European Patent Office (EPO). The patent designates 38 contracting states, including the United Kingdom, and once validation procedures are completed in each country, the company will secure rights in major European countries.
Unlike existing fibrin-based hemostatic agents that depend on blood coagulation proteins, InnoSeal Plus DL applies a technology that mimics the molecular structure of mussel adhesive proteins. The company cites as a key strength its potential applicability in patients taking anticoagulants or those with impaired blood coagulation function.
The patent recognizes a “multi-layer structure” design that secures interlayer bonding strength without the need for additional chemical adhesives. The company explained that it is designed to adhere strongly to the surgical site while not sticking to surgical instruments, thereby improving ease of use.
InnoSeal Plus DL is currently in use at Seoul St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital, Changwon Hanmaeum Hospital, and other institutions. Its range of application is being expanded across various departments, including urology, thoracic surgery, orthopedics, trauma centers, and hepatobiliary and pancreatic surgery.
SCL Science plans to use this patent as a springboard to target the German market first. Germany accounts for about 25–30% of the European medical device market and is considered a market with high receptivity to new hemostatic technologies due to active hepatobiliary and pancreatic surgery and laparoscopic surgery. The company also intends to advance concurrently into the Greek market, where it already has an established distribution network.
An SCL Science official said, “Based on our previous experience exporting InnoSeal to Europe and our regulatory response track record, we plan to refine our strategy with notified bodies and distributors,” adding, “We will accelerate the expansion of our domestic and overseas business on the back of the European patent registration.”
Choi Hyun-jung
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
